您的位置: 首页 > 农业专利 > 详情页

Enhancement of tumor response to chemotherapy by activation of the ASMase/ceramide pathway through timed administration of a short-acting anti-angiogenic agent
专利权人:
Memorial Sloan-Kettering Cancer Center
发明人:
Richard Kolesnick,Adriana Haimovitz-Friedman,Evis Sala,Zvi Fuks
申请号:
US15525856
公开号:
US10413533B2
申请日:
2015.11.12
申请国别(地区):
US
年份:
2019
代理人:
摘要:
Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充